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Abstract. In the Netherlands, outpatient oral anticoagulant
therapy is monitored by a System of specialized anticoagula-
tion clinics whose purpose is to make anticoagulant therapy
äs safe and effective äs possible. In this paper we present
the daily routine in one of these anticoagulation clinics (the
Leiden clinic), which serves a catchment area with about
500,000 inhabitants. Several levels of quality control can be
distinguished in the anticoagulation clinic. One level is the
evaluation and standardization of laboratory methods, which
includes participation in multicentered quality assurance
programs. A second level is therapeutic quality control,
which is the evaluation of how well a clinic maintains the
patients within the specified target ränge of anticoagulant
intensity. A third level is clinical quality control, which in-
cludes clinical outcome research. Outcome research includes
studies into complications associated with treatment (e.g.,
bleeds), risk factors of treatment, and the optimal intensity
of anticoagulant treatment.
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Quality controi is at the core of anticoagulant ther-
apy. It is the raison d'etre of the System of specialized
anticoagulation clinics in the Netherlands [1]. Quality
control Starts with maintaining reliable and repro-
ducible laboratory methods. It includes therapeutic
quality control, which is the evaluation of how well
patients are maintained at the desired intensity of an-
ticoagulation. Clinical quality control is the evaluation
of unwanted side effects of treatment (notably
bleeds), and the evaluation of overall outcome of oral
anticoagulant therapy, efficacy, and safety.
Quality control activities are motivated by a contin-
uous effort to improve the care of patients. It includes
participation in standardization programs and mul-
ticenter quality assurance programs to maintain the
highest laboratory Standards; efforts to extend the
time spent by patients in the therapeutic ränge by
ongoing training and feedback to all medical and para-
medical staff involved in patient care; and mainte-
nance of a sensitive System to record bleeds. Research
is also a form of quality control. Research on the fre-
quency of bleeds and the optimal intensity of oral anti-
coagulant therapy in order to optimize the balance of
therapeutic effect and side effects may be translated
to improved quality of patient care.
The Dutch System
The Netherlands is a densely populated country at the
North Sea with almost 16 million inhabitants. Seventy
geographical regions are served by anticoagulation
clinics [2]. Every patient who needs anticoagulant
therapy is referred to the clinic in his or her region
for anticoagulant monitoring. Since reimbursement is
based on participation in this System of specialized
anticoagulation clinics, very few, if any, patients re-
ceive outpatient treatment with coumarin outside this
System.
Taken äs a group, the anticoagulation clinics form
the Federation of Dutch Thrombosis Services, which
is an organization that sets guidelines for treatment,
facilitates laboratory quality control, organizes Con-
ferences and postgraduate training, promotes re-
search, and publishes its own newsletter. In addition
to its Dutch members, the federation includes two an-
ticoagulation clinics that are located in Spain, and pro-
vides Service in areas where many Dutch elderly live
in the winter.
Two types of coumarin derivatives are licensed for
oral anticoagulant therapy in the Netherlands: short-
acting acenocoumarol (Sintrom mitis®) and long-acting
phenprocoumon (Marcoumar®). The federation has es-
tablished three target INRs for the intensity of anti-
coagulation: INR of 3.0 for venous thromboprophy-
laxis, INR of 3.5 for arterial thromboprophylaxis, and
INR of 4.0 for prophylaxis of thromboemboli in pa-
tients with mechanical heart valves (Table 1). Overall
figures on quality control collected by the federation
show that in l year, up to 65% of INRs are within
these target ranges, about 25% are below, and about
10% are over the desired ränge.
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Table 1. Indications and target intensities for oral
anticoagulant therapy Federation ofDutch Thrombosis
Services recommendations
INR Indication
2 5-3 5 Prophylaxis of venous thrombosis after surgical m-
terventions, durmg immobihzation, after recur-
rent venous thrombosis
Treatment of venous thrombosis m acute deep vem
thrombosis, m acute pulmonary embohsm
3 0-4 5 Prophylaxis of artenal thrombosis after myocardial
mfarction, after ischemic stroke, m atnal flbnlla-
tion, m cardiomyopathy, after coronary bypass or
PTCA, m angina pectons, m penpheral artenal
disease, m heart valve disease
3 6-4 8 Prosthetic heart valves
PTCA = percutaneous translummal coronary angioplasty
Leiden Anticoagulation Clinic
The anticoagulation clinic for the city of Leiden serves
äs an example of a Dutch clinic. It takes care of the
monitoring of outpatient anticoagulant therapy for pa-
tients in the region of Leiden. This region includes
the city of Leiden äs well äs a rural area and serves,
in total, an area with about 500,000 inhabitants. Ap-
proximately 7000 patients are treated annually by the
Leiden Anticoagulation clinic (l in every 70 inhabit-
ants of the region receive short- or long-term treat-
ment with coumarin in a given year). The Leiden An-
ticoagulation Clinic is closely associated with the
Department of Hematology, Section of Hemostasis
and Thrombosis of the University Hospital Leiden,
and also monitors anticoagulation with coumarin and
heparm in inpatients of the hospital. (Because a Dutch
anticoagulation clinic does not usually monitor inpa-
tient care, we will not discuss it further here.)
Approximately 500 patients are seen daily by a
nurse of the anticoagulation climc at the clinic, at
small facilities throughout the region, or at the home
of bedridden patients. The nurse, who is specialized
in anticoagulant care, has a central role m the System.
She sees the patients personally and takes a small
standardized medical history, with regard to bleeds,
other diseases, and change of medication. The nurse
educates the patient, especially about when to contact
the anticoagulation clinic between visits. Finally, the
nurse has a central role in communicating patient in-
formation back to the physician.
Prothrombm times are measured at the anticoagu-
lation clinic from the specimens brought by the nurse;
a bar-code reader enters patient identification into the
Computer System; the prothrombin time, converted
into an INR, is directly transferred to the Computer
System; and if necessary, the nurse adds specific Infor-
mation from the medical interview.
The dosage and time interval to the next checkup
are decided by specialized physicians, assisted by a
Computer algorithm that suggests a dosage and time
period for stabilized patients. The physicians either
authorize the suggested dosage or enter a specific dos-
age directly into the Computer. The physicians specify
a mean daily dosage, which is translated into the spe-
cific dose for each day by the algorithm.
After dosages and time intervals are determined
for all patients, the Computer prints a calendar for
each patient, indicating how many tablets to take each
day. These calendars are sent by mail and arrive the
next morning. On these calendars a bar-code label is
printed, which can be peeled off, and is stuck to the
Vacutainer at the next blood draw. In case immediate
action is required, for example, in extremely overanti-
coagulated patients, patients are contacted by phone.
The time period between visits varies from l to 6
weeks, with an average slightly over 3 weeks.
The Leiden anticoagulation System has been com-
puterized since 1973 [3]. This System generates a dose
prescription in 55% for all prothrombin times mea-
sured. It further helps to orgamze the appointments
for visits or house calls by the nurses, and to generate
daily overviews for quality control, for example, of
patients for whom the dosage was changed by more
than 15% and of the number of INRs within the thera-
peutic ränge.
Therapeutic Quality Control
One of the most important aims for anticoagulant
therapy monitoring is to maintain prothrombin times
within the target zone. There are several ways to ex-
press the success of this effort [4-6]. A simple propor-
tion of INRs within the therapeutic ränge gives an
unduly pessimistic result because patients who are un-
stable are seen most often [7].
We recently proposed a method that assumes a lin-
ear change of the INR between visits and counts the
number of days spent by all patients at different
INRs, similar to the categorized person-time methods
used to calculate incidence rates [8]. This method can
be used for two distinct purposes: (1) to express the
therapeutic quality of anticoagulation äs the propor-
tion of the total observation time of all patients that
was spent in the target zone; (2) to relate the person-
time at various INRs to the INRs observed at adverse
events, and from that to calculate the risk of these
events at different intensities of anticoagulation. We
have used this method in several studies, two of which
are described here.
Clinical Quality Control
In l year, a total of almost 7000 patients were treated
with oral anticoagulants at the Leiden anticoagulation
clinic, most with long-term treatment. These patients
had a mean age of 66 years, with all ages represented,
from the young to the very old. About two thirds of
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all patients were men, with the predominance of men
completely explained by a higher prevalence of arte-
rial disease among men (Table 2).
Much of the efforts in an anticoagulation clinic are
aimed at the reduction of side effects, especially
bleeds. We analyzed the experience of our patients
over a 1-year period, to assess which factors contrib-
uted to the risk of bleeding [9]. We classified all bleeds
that were fatal, intracranial, or that required hospital
admission, tranfusions, or surgical interventions, äs
well äs all bleeds in muscles and joints, äs major
bleeding.
The overall frequency of major bleeds was 2.7 per
100 patient-years, that is, 2.7% per year (95% CI
2.3-3.1%). The incidence of intracranial bleeding was
0.62 per 100 patient-years, and the incidence of fatal
bleeding was 0.64 per 100 patient-years. Over half of
all bleeding-related deaths were caused by hemor-
rhagic strokes. These bleeding rates are similar to
those found in other studies, although there have been
reports of higher [10] äs well äs lower rates [11]. Much
of the discrepancy appears to be related to patient
selection criteria. Selection of complying patients with
limited or no co-morbidity for a randomized trial may
reduce the observed incidence of bleeds. An incidence
of 2-4% per year probably reflects what can be
reached in a clinic dedicated to anticoagulation ther-
apy in unselected patients.
Can this risk of bleeding be reduced further? One
approach to this question is to assess which patients
are most at risk of bleeds. In a multivariate regression
model, we looked at several factors that might influ-
ence risk. We found a slight 16% excess of bleeding
in women äs compared with men, with a very wide
confidence interval (95% CI 0.83-1.61, for the relative
risk). The strengest predictors of the bleeding risk
were age and INR, that is, the achieved intensity of
oral anticoagulation äs calculated by the method we
described previously.
For each 10-year increase in age, the risk of bleed-
ing increased 46%, and for each unit increase in INR,
the frequency of bleeds rose by 42%. In absolute fig-
ures, the risk of major bleeds was still less than 2%
in those aged 45-64, but rose to over 5% in those
aged 75 and older. These findings imply that older
individuals with a higher INR will have a severalfold
increase in risk compared with that of younger indi-
viduals with a lower INR.
In this study, we looked at bleeding complications
only, not at the prevention of thromboembolic events.
Therefore, we cannot derive recommendations from
it regarding the intensity of anticoagulation, and spe-
cifically cannot recommend the use of lower INRs for
older patients, since we have no information on the
rate of thromboembolization in relation to age and
INR. It does follow from these results, however, that
it is especially worthwhile to attempt to avoid over-
anticoagulation in the elderly, which may be achieved
by more frequent monitoring.
Optimal Intensity of Oral
Anticoagulation
When a treatment depends upon such a fme balance
of therapeutic effect and side effect, finding the right
dosage becomes crucial. Anticoagulation clinics with
dedicated physicians and nurses are designed to main-
tain this balance and to maintain the patients on the
desired intensity of anticoagulation äs long äs possi-
ble. Research is needed to find which intensity is opti-
mal, that is, which will offer the lowest risk of throm-
boembolic and bleeding complications. This research
is hampered by the Variation of INRs over time. A
randomized clinical trial, in which two target INRs or
target ranges are compared, will therefore not deter-
mine which intensity is optimal: It will compare two
strategies, which will not have been maintained all of
the time in all of these patients due to the normal
Variation of the INR.
We reasoned that the optimal intensity would be
the intensity at which the frequency of complications
was lowest, supposing that we were able to maintain
that intensity all of the time. Therefore, we calculated
the incidence of complications over the whole ränge
of achieved INRs, by the method mentioned earlier
[8]. With this method, for each intensity the incidence
of events is calculated äs the number of events oc-
curring at that INR divided by the total person-time
spent at that INR. This is the Standard way to calcu-
late incidence rates, with the main difference being
Table 2. Ckaracteristics of the patients at the Leiden Anticoagulation Clinic
Men Women
Arterial disease Other indications Arterial disease Other indications Overall
Number of patients
Patient years
Major bleeds (n)
Major bleeds (%/yr)
Fatal bleeds (n)
Fatal bleeds (%/yr)
3511
3268
66
2.0
12
0.4
1106
926
35
3.8
14
1.5
1103
1004
26
2.6
4
.06
1094
887
35
4.0
10
0.8
6814
6085
162
2.7
39
0.6
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that the person-time at each INR is contributed to by
different patients.
A problem, in addition to this distribution of the
person-time of each patient over the various intensi-
ties, is to estimate the INR in each patient on each
individual day. Obviously, this is not known, but a
reasonable estimate is a linear Interpolation between
successive visits. This way of deriving "INR-days" is
depicted in Figure 1. The person-time of the füll co-
hort is distributed in INR-specific person-time in this
way. Subsequently, for all patients with events, the
INR at the time of the event is obtained from patient
records or hospital charts. For each INR, the inci-
dence of events at that intensity is then calculated äs
all events occurring at that INR divided by the total
person-time at that INR.
The incidence rates calculated in this fashion are
our best estimate of the frequency of untoward events
at different intensities of anticoagulation, if one were
able to maintain patients at each of these intensities
permanently. This may be viewed äs the "ideal phar-
macological" effect of anticoagulation, which may sub-
sequently serve to set target INRs and target ranges,
and to design studies aimed at improving the stability
of anticoagulation therapy.
Leiden Artifitial Valves and
Anticoagulation Study (LAVA)
Patients with artificial heart valves are at high risk of
valve thrombosis and embolization. Therefore, they
receive the most intense anticoagulant therapy, and
are also most at risk of bleeding [12]. Because stnking
the proper balance between thromboemboli and bleed-
ing is most critical in this patient group, we set out
to assess the optimal intensity of anticoagulation [13].
We followed 1608 patients from four anticoagula-
tion clinics over an average 4 years and registered
all INR measurements over this period and all major
complications, bleeds, and thromboemboli. We calcu-
lated the incidence of these untoward events for each
intensity of anticoagulation.
Over 6475 years of follow-up, we registered 210
(3.5 per 100 patient-years) major events, 45 throm-
boemboli (0.7 per 100 patient-years), and 164 major
bleeds (2.7 per 100 patient-years). Strokes occurred
in 93 patients (1.4 per 100 patient-years), and fatal
bleeding in 20 patients (0.30 per 100 patient-years).
The incidence of untoward events was strongly de-
pendent on the intensity of anticoagulation (Figure
2). Whereas the overall incidence was 3.5% per year,
it was 2% when INRs between 2.5 and 4.9 were
achieved. It increased sharply with lower INRs to
7.5% per year for INR 2.0-2.5 up to 27% per year for
achieved INRs between 1.0 and 1.4. This increased
risk in under-anticoagulated patients was due to in-
creasing rates of embolism; when INRs higher than
4.9 were achieved, the frequency of bleeding rose
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Fig. 1. Method to calculate INR-specific incidence rates The
figure represents one patient, who has been seenfour times be-
tween January 2 and 16 (marked by asterisks), with actual
INR values 0/25,35,1 0, and h 5 measured at those visits
When a linear change of the INR between visits is assumed,
achieved INR can be assignedfor each day 2 5 at 1/2, 2 75
at 1/3, 30 at 1/3, and so on The day s at each INR will be
summed, per patient (so this one patient contnbutes 3 days to
INR 3 0, at 1H, at 1/8, and at 1/15) and then over all ofthe
patients This yields a total person time at each INR, which
is the denommator for the event rate at each INR The numer-
ator is the number of events at each INR, for all patients with
events, äs derivedfrom the patient records
sharply: 4.8 per 100 treatment-years for INR 5.0-5.5,
up to 75 per 100 patient-years at an INR over 6.5.
When we looked only at the classified strokes, the
risk of ischemic stroke went up when the INR was
lower, while for hemorrhagic strokes the risk went up
with increasing intensities of anticoagulation. The
high risk of embolization in under-anticoagulated
patients, and the high risk of bleeding in over-
anticoagulated patients, is reflected in the U-shaped
curve shown in Figure 2. When we limited the analy-
sis to the most severe adverse effects (i.e., only those
that were fatal or led to a lasting handicap with depen-
dency), again the optimal intensity was found between
INRs of 2.5 and 4.9.
These data indicate that when a constant INR was
achievable, the optimal level would lie between 2.5
and 4.9 INR, at which the rate of complications would
be almost halved compared with the current fre-
quency of untoward events. Within this ränge, the
risks did not vary much by INR. Since achieved INRs
will vary within and around target INR ranges, from
these data it follows that a reasonable target ränge
lies between 3.0 and 4.0 INR.
Conclusions
The System of specialized anticoagulation clinics in the
Netherlands has been designed to optimize the treat-
ment of patients who require oral anticoagulants. This
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Fig. 2. Incidence of all adverse events (all thromboemboh, ma-
jor bleeds, and strokes) by intensity of anticoagulation INR-
specific incidence rates for all major adverse events per 100
person-years. The dotted hnes are the 95% confidence inter-
vals around the mcidence (Repnnted by permission of The
New England Journal of Medicine, Cannegieter SC, Rosen-
daal FR, Wmtzen AR et al., 1995;333:11-17. Copyright 1995.
Massachusetts Medical Society. All rights reserved )
treatment will benefit from ongoing quality control,
not only of the laboratory methods, but also of the
Performance of the clinic in maintaining the patients
within a target ränge. Finally, the concentration of
patients allows for studies designed to further im-
prove care by investigating risk factors for complica-
tions and by assessing the safest intensity of anticoag-
ulation.
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